Personalizing
Cancer Treatment for Everyone

PARP Inhibitor Active in Non-BRCA Breast Tumors

Suggests expanded potential in triple-negative tumors

November 13, 2017

By Arturo Loaiza-Bonilla, MD, MSEd

A PARP inhibitor demonstrated activity in triple-negative breast cancer (TNBC) xenografts without BRCA1/2 mutations, investigators reported online in Clinical Cancer Research.
Derived from primary and recurrent tumor specimens obtained from 25 patients, the xenografts represented all TNBC subtypes and harbored heterogeneous genomic alterations. Treatment with PI3K, mTOR, and MEK inhibitors slowed tumor growth but did not cause tumor regression.
In contrast, five of 12 xenografts treated with the PARP inhibitor talazoparib had dramatic tumor regression. Four of the five talazoparib-sensitive xenografts did not harbor germline BRCA1/2 mutations, although several had somatic alterations in homologous repair pathways.
Loaiza-Bonilla is affiliated with Cancer Treatment Centers of America. 

Click here to see original article

Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us by one of the options listed below:
PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top